ESSA Pharma Inc. Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Essa Pharma Inc. |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, sec-filing
TL;DR
ESSA Pharma filed an 8-K on May 8, 2025, updating its financial condition.
AI Summary
ESSA Pharma Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on ESSA Pharma Inc.'s financial condition, which is crucial for investors to assess the company's performance and stability.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- ESSA Pharma Inc. (company) — Registrant
- May 8, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by ESSA Pharma Inc.?
The primary purpose of this 8-K filing is to report on ESSA Pharma Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of May 8, 2025.
What is the company's legal name and place of incorporation?
The company's exact name is ESSA Pharma Inc., and it is incorporated in British Columbia, Canada.
What is ESSA Pharma Inc.'s principal executive office address?
ESSA Pharma Inc.'s principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5.
What is the SIC code for ESSA Pharma Inc.?
The Standard Industrial Classification (SIC) code for ESSA Pharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding ESSA Pharma Inc..